[go: up one dir, main page]

AR104805A1 - Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet - Google Patents

Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet

Info

Publication number
AR104805A1
AR104805A1 ARP160101552A ARP160101552A AR104805A1 AR 104805 A1 AR104805 A1 AR 104805A1 AR P160101552 A ARP160101552 A AR P160101552A AR P160101552 A ARP160101552 A AR P160101552A AR 104805 A1 AR104805 A1 AR 104805A1
Authority
AR
Argentina
Prior art keywords
methods
cancer
response
subject
bet
Prior art date
Application number
ARP160101552A
Other languages
English (en)
Inventor
Mesh Kathryn
L Mcleland Mark
Firestein Ron
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR104805A1 publication Critical patent/AR104805A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos de tratamiento de un sujeto que tiene cáncer con un inhibidor de BET, métodos de selección de un sujeto para el tratamiento con un inhibidor de BET, métodos de predicción de la capacidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET, métodos de comunicación de la probabilidad de respuesta de un sujeto que tiene cáncer a un inhibidor de BET y métodos de modulación del tratamiento de un sujeto que se somete a un tratamiento con inhibidores de BET para cáncer. Los métodos descritos incluyen las etapas para llevar a cabo un ensayo de detección a base de ácido nucleico para detectar el nivel de expresión de un eARN transcrito de un elemento potenciador asociado con mic en una muestra que contiene células cancerosas del sujeto y determinar el nivel de expresión del eARN en las células en la muestra.
ARP160101552A 2015-05-29 2016-05-27 Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet AR104805A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562168691P 2015-05-29 2015-05-29

Publications (1)

Publication Number Publication Date
AR104805A1 true AR104805A1 (es) 2017-08-16

Family

ID=56117996

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101552A AR104805A1 (es) 2015-05-29 2016-05-27 Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet

Country Status (2)

Country Link
AR (1) AR104805A1 (es)
WO (1) WO2016196065A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
WO2019113260A1 (en) * 2017-12-05 2019-06-13 The Regents Of The University Of Colorado A Body Corporate Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof
WO2020227213A1 (en) * 2019-05-03 2020-11-12 Icahn School Of Medicine At Mount Sinai Methods of controlling and improving brain health
WO2021180055A1 (zh) * 2020-03-09 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 一种brd4抑制剂的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
EA001732B1 (ru) 1996-09-13 2001-08-27 Велфайд Корпорейшн Тиенотриазолодиазепиновые соединения и лекарственное средство
AU2001249727A1 (en) 2000-03-31 2001-10-15 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
MX374414B (es) 2009-04-22 2025-03-06 Resverlogix Corp Nuevos agentes anti-inflamatorios.
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2779423C (en) 2009-11-05 2018-08-14 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
AU2012220620A1 (en) 2011-02-23 2013-10-03 Icahn School Of Medicine At Mount Sinai Inhibitors of bromodomains as modulators of gene expression
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9328117B2 (en) 2011-06-17 2016-05-03 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2861255B1 (en) * 2012-06-19 2019-10-09 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy

Also Published As

Publication number Publication date
WO2016196065A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EP4368992A3 (en) Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
EA201991105A1 (ru) Методы оценки риска с использованием общей и специфической неклеточной днк
AR102518A1 (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40
BR112016008970A2 (pt) Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
MX386750B (es) MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
MX2019010844A (es) Analisis del transcriptoma de plasma materno mediante secuenciacion de arn en paralelo a gran escala.
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
SA518392005B1 (ar) تحديد خصائص التسلسل العميق للأورام
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
MX368815B (es) Método y dispositivo para analizar relación social.
MX360236B (es) Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
JOP20190280A1 (ar) مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2017003387A (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogenetica de cancer colorrectal metastasico.
MX2016013877A (es) Composiciones y metodos para mejorar y/o predecir la amplificacion de adn.
AR104805A1 (es) Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet
PH12015501778A1 (en) Markers associated with wnt inhibitors
CL2017001929A1 (es) Método y producto
MX2019007894A (es) Composiciones y metodos para detectar el adn tumoral circulante.
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
EP3498275C0 (en) USE OF COMPOUNDS KNOWN AS D-AMINOACID OXIDASE INHIBITORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure